Loading...
Inovio Pharmaceuticals, Inc.
GBMB.F•XETRA
Healthcare
Biotechnology
€0.55
€0.02(4.15%)
Inovio Pharmaceuticals, Inc. (GBMB.F) AI-Powered Stock Analysis
See how Inovio Pharmaceuticals, Inc. scores across key metrics like financial growth, valuation, and market position using AI-driven evaluation.
Model Information
The AI Stock Analysis Model is provided for informational purposes only and should not be considered financial advice. We are continously improving this model to increase accuracy and performance.Read our Full DisclaimerInovio Pharmaceuticals, Inc. (GBMB.F) Stock Overall Grade
Inovio Pharmaceuticals, Inc.’s grade based on a comprehensive AI analysis of financial metrics, growth potential, and market position.
B
Good
Grade Breakdown by Metric
See how each financial and market factor contributes to Inovio Pharmaceuticals, Inc.'s overall stock rating.
Forecast
C+Score
55/100Financial Growth
CScore
40/100Fundamental Growth
C+Score
50/100Key Ratios
C+Score
55/100Sector Comparison
B+Score
75/100Industry Comparison
B+Score
75/100S&P 500 Benchmark
AScore
85/100Analyst Consensus
C+Score
50/100Inovio Pharmaceuticals, Inc. (GBMB.F) AI-Powered Stock Analysis
This asset demonstrates Good performance with an overall Forecast Score of 55/100 (C+), reflecting weak confidence in its potential. Financial Growth (40/100, C) and Fundamental Growth (50/100, C+) highlight its stability, while Key Ratios (55/100, C+) and Sector Comparison (75/100, B+) indicate solid positioning. Compared to broader benchmarks like the S&P 500 (85/100, A), it shows competitive strength. Analyst Consensus (50/100,C+) suggests High divergence in outlook.Component Analysis Explained
Understand the key factors behind each Inovio Pharmaceuticals, Inc. stock grade, including financials, comparisons, and forecasts.